To print: Select File and then Print from your browser's menu

Title: Post-Marketing Surveillance With Gabapentin Reveals Only Previously Documented Neurological Side Effects

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12199723&dopt=Abstract

Epilepsia 2002 Sep;43(9):983-92. "A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England"
10/25/2002 03:11:41 PM
By Alison Palkhivala

A post-marketing surveillance of gabapentin found that although the drug caused the expected neurological side effects such as drowsiness, dizziness and lassitude, there were no unrecognized adverse events. L. V. Wilton and S. Shakir from the Drug Safety Research Unit, Southampton, England, conducted this on the use of gabapentin as an add-on therapy for the treatment of epilepsy. They identified patients taking gabapentin in this manner from records about dispensing of prescriptions kept by the National Health Service. Approximately six months after the initial prescription, the investigators sent the patients' physicians questionnaires about the patient demographics and use of gabapentin. Among the 3,100 patients who comprised the cohort of this observational study, 136 were children. The median duration of gabapentin use among these patients was 8.1 months. The most frequently reported adverse events during the first month of treatment were drowsiness/sedation, dizziness and malaise/lassitude. These adverse events were also the ones most commonly cited as reasons for discontinuing the drug. Eleven women in the cohort used gabapentin during the first trimester of their pregnancy, and none gave birth to babies with congenital abnormalities. Crude mortality rate among the patients taking gabapentin was five times that of the general population but no higher than those reported by other studies.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12199723&dopt=Abstract

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.